SG11202112144RA - Modulators and modulation of the receptor for advanced glycation end-products rna - Google Patents
Modulators and modulation of the receptor for advanced glycation end-products rnaInfo
- Publication number
- SG11202112144RA SG11202112144RA SG11202112144RA SG11202112144RA SG11202112144RA SG 11202112144R A SG11202112144R A SG 11202112144RA SG 11202112144R A SG11202112144R A SG 11202112144RA SG 11202112144R A SG11202112144R A SG 11202112144RA SG 11202112144R A SG11202112144R A SG 11202112144RA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- receptor
- modulation
- advanced glycation
- glycation end
- Prior art date
Links
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 title 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901641A AU2019901641A0 (en) | 2019-05-14 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902095A AU2019902095A0 (en) | 2019-06-17 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902772A AU2019902772A0 (en) | 2019-08-02 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019903900A AU2019903900A0 (en) | 2019-10-16 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| PCT/AU2020/050449 WO2020227758A1 (en) | 2019-05-14 | 2020-05-07 | Modulators and modulation of the receptor for advanced glycation end-products rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112144RA true SG11202112144RA (en) | 2021-11-29 |
Family
ID=73290056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112144RA SG11202112144RA (en) | 2019-05-14 | 2020-05-07 | Modulators and modulation of the receptor for advanced glycation end-products rna |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11441148B2 (en) |
| EP (1) | EP3969590A4 (en) |
| JP (1) | JP2022533358A (en) |
| KR (1) | KR20220009971A (en) |
| CN (1) | CN114127288A (en) |
| AU (1) | AU2020276337A1 (en) |
| BR (1) | BR112021022714A2 (en) |
| CA (1) | CA3140209A1 (en) |
| IL (1) | IL288040A (en) |
| MX (1) | MX2021013858A (en) |
| SG (1) | SG11202112144RA (en) |
| WO (1) | WO2020227758A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114127288A (en) | 2019-05-14 | 2022-03-01 | 莫纳什大学 | Modulators and modulation of advanced glycosylation end product receptor RNA |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| DE69636289T2 (en) | 1995-12-18 | 2007-05-10 | Angiodevice International Gmbh | NETWORKED POLYMERISATE MATERIALS AND METHOD FOR THEIR USE |
| JP2002510319A (en) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | Compositions and methods for delivery of oligonucleotides through the gastrointestinal tract |
| WO2000050050A1 (en) | 1999-02-23 | 2000-08-31 | Isis Pharmaceuticals, Inc. | Multiparticulate formulation |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| JP2008539698A (en) * | 2005-04-29 | 2008-11-20 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Methods and compositions for regulation of nucleic acid expression at the post-transcriptional level |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| JP2010233542A (en) * | 2009-03-31 | 2010-10-21 | Kanazawa Univ | Primer set and probe capable of distinguishing and amplifying two kinds of splicing variants of rage gene |
| US20100303776A1 (en) * | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
| JP2014524323A (en) | 2011-08-25 | 2014-09-22 | ディービー、イクイップメント、アクティーゼルスカブ | Accessory bag with reinforced side walls and variable length |
| AU2019270189A1 (en) * | 2018-05-17 | 2021-01-14 | Lifesplice Pharma Llc | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use |
| CN114127288A (en) | 2019-05-14 | 2022-03-01 | 莫纳什大学 | Modulators and modulation of advanced glycosylation end product receptor RNA |
-
2020
- 2020-05-07 CN CN202080044288.6A patent/CN114127288A/en active Pending
- 2020-05-07 KR KR1020217039458A patent/KR20220009971A/en active Search and Examination
- 2020-05-07 JP JP2021568406A patent/JP2022533358A/en active Pending
- 2020-05-07 EP EP20806464.2A patent/EP3969590A4/en active Pending
- 2020-05-07 MX MX2021013858A patent/MX2021013858A/en unknown
- 2020-05-07 WO PCT/AU2020/050449 patent/WO2020227758A1/en unknown
- 2020-05-07 BR BR112021022714A patent/BR112021022714A2/en unknown
- 2020-05-07 AU AU2020276337A patent/AU2020276337A1/en active Pending
- 2020-05-07 CA CA3140209A patent/CA3140209A1/en active Pending
- 2020-05-07 SG SG11202112144RA patent/SG11202112144RA/en unknown
-
2021
- 2021-08-25 US US17/411,932 patent/US11441148B2/en active Active
- 2021-11-11 IL IL288040A patent/IL288040A/en unknown
-
2022
- 2022-09-07 US US17/930,364 patent/US11674143B2/en active Active
-
2023
- 2023-05-01 US US18/310,289 patent/US20240141360A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230015481A1 (en) | 2023-01-19 |
| EP3969590A1 (en) | 2022-03-23 |
| US11674143B2 (en) | 2023-06-13 |
| KR20220009971A (en) | 2022-01-25 |
| JP2022533358A (en) | 2022-07-22 |
| CA3140209A1 (en) | 2020-11-19 |
| US20240141360A1 (en) | 2024-05-02 |
| EP3969590A4 (en) | 2024-05-15 |
| MX2021013858A (en) | 2022-03-22 |
| US11441148B2 (en) | 2022-09-13 |
| WO2020227758A1 (en) | 2020-11-19 |
| US20210388363A1 (en) | 2021-12-16 |
| IL288040A (en) | 2022-01-01 |
| CN114127288A (en) | 2022-03-01 |
| WO2020227758A8 (en) | 2021-11-18 |
| BR112021022714A2 (en) | 2022-01-18 |
| AU2020276337A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3867216A4 (en) | Androgen receptor modulators and methods for their use | |
| IL277398A (en) | Pd-l1 binding affimers, and uses related thereto | |
| EP3873923A4 (en) | Multivalent regulatory t cell modulators | |
| IL292156A (en) | Substituted azacyles as trmp8 modulators | |
| EP3642243A4 (en) | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction | |
| EP4076423A4 (en) | Trpml modulators | |
| SG11202107209WA (en) | Systems and methods for modulating rna | |
| IL288858A (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators | |
| EP3698305A4 (en) | Authenticating and paying for services using blockchain | |
| EP3672982A4 (en) | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage) | |
| EP3541790A4 (en) | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use | |
| ZA202105847B (en) | Mtroc modulators and uses thereof | |
| EP3930722A4 (en) | Treatment with p2x3 modulators | |
| EP3364622A4 (en) | Modulator, modulation system and method for realizing high-order modulation | |
| EP3737389A4 (en) | Method for modulating metabolism | |
| GB2585803B (en) | Electro-absorption modulator | |
| EP3454845A4 (en) | Adrenergic receptor modulating compounds and methods of using the same | |
| IL288040A (en) | Modulators and modulation of the receptor for advanced glycation end-products rna | |
| IL286681A (en) | Compounds and methods for modulating ube3a-ats | |
| EP4049747A4 (en) | Liquid phase reactor and application thereof | |
| EP3765574A4 (en) | Detachable adhesive composition, systems and methods | |
| EP3765020A4 (en) | Spirocyclic ror-gamma modulators | |
| AU2019903900A0 (en) | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902772A0 (en) | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902095A0 (en) | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA |